Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery

Tao Zhang

Status and phase: Completed; Phase 4

Conditions: Patients Undergoing Endoscopic Sinus Surgery

Treatments: Drug: saline; Drug: Desmopressin

Study type: Interventional

Funder types: Other

Identifiers

NCT02125188

desmopressinFESS

Details and patient eligibility

About

Bleeding during functional endoscopic sinus surgery (FESS) is a challenge for both surgeons and anesthesiologists despite several measures available for improving the surgical field. This study was conducted to evaluate the effect of desmopressin on blood loss and the quality of the surgical field in FESS.

Full description

Desmopressin, a synthetic analogue of vasopressin, has been employed as a non-transfusional treatment for hemophilia and von Willebrand's disease. Hemostatic effects of desmopressin include: 1) an increase in plasma factors through endogenous release of coagulation factor VIII, von Willebrand factor and tissue plasminogen activator; 2) an increase in platelet adhesiveness; and 3) a reduction in bleeding time. Randomized, double-blind studies have been performed on patients undergoing various types of surgical procedures. A study in patients undergoing orthognathic surgery showed a significant reduction in intraoperative blood loss and a study in patients undergoing lumbar fusion concluded that desmopressin was effective in reducing intraoperative blood loss. The purpose of this study was to investigate the effect of administration of desmopressin on intraoperative blood loss in patients undergoing FESS.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Society of Anesthesiologists physical status I-II
• aged 18-60 years

Exclusion criteria

• Patients receiving anticoagulants
• medically important liver or kidney dysfunction
• significant heart disease
• allergy to Desmopressin

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

Desmopressin

Experimental group

Description:

Desmopressin 3ug/kg in saline 100ml ivdrip before surgery

Treatment:

Drug: Desmopressin

saline

Placebo Comparator group

Description:

saline 100ml ivdrip before surgery

Treatment:

Drug: saline